JGR Capital Partners Orgenesis Latest Research (ORGS)
This page is dedicated to JGR Capital’s Orgenesis Latest Research.
Orgenesis is a biopharmaceutical company with a focus on cell therapy development and manufacturing. The company focuses primarily on assisting insulin-dependent diabetes patients. Orgenesis trades as ORGS on OTCMKTS. The biopharmaceutical firm was founded in 2008 in Maryland, where its headquarters remain.
|Range||0.37 - 0.40|
|52 week||0.28 - 0.98|
|Vol / Avg.||10,500.00/24,960.00|
|Q3 (Aug '17)||2016|
|Net profit margin||-76.23%||-143.72%|
|Return on average assets||-21.26%||-25.46%|
|Return on average equity||-74.08%||-71.84%|
Officers and directors
|Vered Caplan||Chairman of the Board, Chief Executive Officer, President; Chief Executive Officer of Orgenesis Maryland Inc.|
|Neil T. Reithinger CPA||Chief Financial Officer, Treasurer, Secretary|
|Sarah Ferber Ph.D.||Chief Scientific Officer|
|David Sidransky M.D.||Director|
For more information on Orgenesis: